Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Effects of BMI on PFS in the MONARCH 1 and MONARCH 2 trial

Evandro de Azambuja • 22 May 2020
ESMO Breast 2020
Breast Cancer Abemaciclib
MONARCH 1 MONARCH 2

Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, reports small decreases in PFS for obese patients treated with CDK4/6 inhibitors and endocrine therapy in the MONARCH 1 (NCT02102490) and MONARCH 2 (NCT02107703) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Evandro de Azambuja

2:01
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker in breast cancer
Evandro de Azambuja • 12 Sep 2022
1:14
Prognostic value of beta-2 adrenergic receptor levels in HER2+ breast cancer
Evandro de Azambuja • 12 Sep 2022
6:09
Adjuvant endocrine therapy for breast cancer: optimal durations and regimens
Evandro de Azambuja • 12 Sep 2022
2:06
NGS multi-panel gene testing for newly diagnosed patients with metastatic breast cancer
Evandro de Azambuja • 18 Sep 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals